tirzepatide sglt2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial and anti Development of tirzepatide and the

These findings suggest that while ketogenic interventions show promise in improving symptoms in PD, their metabolic efficacy may be significantly limited in patients with type 2 diabetes

However, cross-trial comparison consistently shows Tirzepatide producing 36% greater body weight reduction at maximum doses

Competing interests AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, and Takeda

Sundin OH, Mendoza-Ladd A, Morales E, et al

Plans are more likely to cover a GLP-1 for an FDA-approved use such as type 2 diabetes, and many employer plans still exclude weight-loss coverage entirely

Albrecht J, Norenberg MD (2006) Glutamine: a Trojan horse in ammonia neurotoxicity